C WorldWide Group Holding A S Grows Stock Position in Vaxcyte, Inc. $PCVX

C WorldWide Group Holding A S lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 105.3% in the 2nd quarter, Holdings Channel.com reports. The firm owned 195,000 shares of the company’s stock after buying an additional 100,000 shares during the quarter. C WorldWide Group Holding A S’s holdings in Vaxcyte were worth $6,339,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the stock. Bank of New York Mellon Corp raised its stake in shares of Vaxcyte by 7.6% during the second quarter. Bank of New York Mellon Corp now owns 449,694 shares of the company’s stock worth $14,620,000 after purchasing an additional 31,680 shares during the last quarter. Bank of Montreal Can grew its holdings in Vaxcyte by 4.2% during the second quarter. Bank of Montreal Can now owns 31,547 shares of the company’s stock worth $1,026,000 after acquiring an additional 1,274 shares during the period. Atria Investments Inc grew its holdings in Vaxcyte by 11.1% during the second quarter. Atria Investments Inc now owns 6,816 shares of the company’s stock worth $222,000 after acquiring an additional 683 shares during the period. Jennison Associates LLC grew its holdings in Vaxcyte by 24.3% during the second quarter. Jennison Associates LLC now owns 1,399,299 shares of the company’s stock worth $45,491,000 after acquiring an additional 273,579 shares during the period. Finally, Teacher Retirement System of Texas grew its holdings in Vaxcyte by 3.4% during the second quarter. Teacher Retirement System of Texas now owns 31,210 shares of the company’s stock worth $1,015,000 after acquiring an additional 1,026 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Performance

Vaxcyte stock opened at $40.32 on Thursday. The firm has a market capitalization of $5.23 billion, a price-to-earnings ratio of -8.33 and a beta of 1.07. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $116.00. The stock’s fifty day moving average is $37.66 and its two-hundred day moving average is $34.87.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same quarter in the prior year, the business earned ($0.83) earnings per share. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Tuesday, October 14th. Finally, The Goldman Sachs Group assumed coverage on Vaxcyte in a report on Friday, September 12th. They set a “neutral” rating and a $38.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $106.25.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.